The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome
Open accessAbstract
Incidence of liver disease (LD) associated with cystic fibrosis (CF) and its clinical characterization still is unsettled. We have assessed prospectively the incidence and risk factors of this complication, and its impact on the clinical course of CF. Between 1980 and 1990, we enrolled 177 CF patients without LD in a systematic clinical, laboratory, ultrasonography screening program of at least a 10-year duration. During a 14-year median follow-up (2,432 patient-years), 48 patients developed LD, with cirrhosis already present in 5. Incidence rate (number of cases per 100 patient-years) was 1.8% (95% confidence interval: 1.3-2.4), with sharp decline after the age of 10 years and higher risk in patients with a history of meconium ileus (incidence rate ratio, 5.5; 2.7-11), male sex (2.5; 1.3-4.9), or severe mutations (2.4; 1.2-4.8) at multivariate analysis. Incidence of cirrhosis was 4.5% (2.3-7.8) during a median period of 5 years from diagnosis of liver disease. Among the 17 cirrhotic patients, 13 developed portal hypertension, 4 developed esophageal varices, 1 developed liver decompensation requiring liver transplantation. Development of LD did not condition different mortality (death rate ratio, 0.4; 0.1-1.5) or higher incidence of other clinically relevant outcomes. In conclusion, LD is a relatively frequent and early complication of CF, whose detection should be focused at the first life decade in patients with history of meconium ileus, male sex, or severe genotype. Although LD does not condition a different clinical course of CF, in some patients it may progress rapidly and require liver transplantation. (Hepatology2002;36:1374-1382).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tanner, J. M., & Whitehouse, R. H. (1976) · Archives of Disease in Childhood · doi:10.1136/adc.51.3.170 · Cited by 3,137 · cited 3×
“Male sex 35 (73%) 9 (64%) 14 (67%) 12 (92%) ,181 Median age, time of first visit (range)-mo 4 (0-49) 3 (0-41) 4 (1-49) 5 (1-28) ,081”
Changes in the normal maximal expiratory flow-volume curve with growth and aging.
Knudson, R. J., Lebowitz, M. D., Holberg, C. J., & Burrows, B. A. (1983) · PubMed · doi:10.1164/arrd.1983.127.6.725 · Cited by 1,907
Prediction of mortality in patients with cystic fibrosis
Kerem, E., Reisman, J., Corey, M., Canny, G. J., & Levison, H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199204303261804 · Cited by 993
The changing epidemiology of cystic fibrosis
FitzSimmons, S. C. (1993) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)83478-x · Cited by 928
Predictive 5-year survivorship model of cystic fibrosis
Liou, T. G., Adler, F. R., FitzSimmons, S. C., Cahill, B. C., Hibbs, J. R., & Marshall, B. C. (2001) · American Journal of Epidemiology · doi:10.1093/aje/153.4.345 · Cited by 749
Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease
Joseph, A. E. A., Saverymuttu, S. H., Al-Sam, S., Cook, M. G., & Maxwell, J. D. (1991) · Clinical Radiology · doi:10.1016/s0009-9260(05)80350-2 · Cited by 515
Stehr, K., Cherry, J. D., Heininger, U., Schmitt-Grohé, S., Überall, M., Laussucq, S., Eckhardt, T., Meyer, M., Engelhardt, R., Christenson, P., et al. (1998) · Pediatrics · doi:10.1542/peds.101.1.1 · Cited by 511
Genotype and Phenotype in Cystic Fibrosis
Zielenski, J. (2000) · Respiration · doi:10.1159/000029497 · Cited by 482
Genetic determination of exocrine pancreatic function in cystic fibrosis.
Kristidis, P., Bozon, D., Corey, M. L., Markiewicz, D., Rommens, J. M., Tsui, L.-C., & Durie, P. R. (1992) · PubMed · Cited by 438
(1993) · Cancer Causes and Control · doi:10.1007/bf00052433 · Cited by 437
Natural history of liver disease in cystic fibrosis
Lindblad, A., Glaumann, H., & Strandvik, B. (1999) · Hepatology · doi:10.1002/hep.510300527 · Cited by 306
Recommendations for Management of Liver and Biliary Tract Disease in Cystic Fibrosis
Sokol, R. J., & Durie, P. R. (1999) · Journal of Pediatric Gastroenterology & Nutrition · doi:10.1097/00005176-199900001-00001 · Cited by 245
Detection of a cystic fibrosis modifier locus for meconium ileus on human chromosome 19q13
Zielenski, J., Corey, M., Rozmahel, R., Markiewicz, D., Aznarez, I., Casals, T., Larriba, S., Mercier, B., Cutting, G. R., Krebsova, A., et al. (1999) · Nature Genetics · doi:10.1038/9635 · Cited by 222
Colombo, C., Battezzati, P. M., Podda, M., Bettinardi, N., & Giunta, A. (1996) · Hepatology · doi:10.1002/hep.510230627 · Cited by 219
Self-citationEstrogens stimulate proliferation of intrahepatic biliary epithelium in rats
Alvaro, D., Alpini, G., Onori, P., Perego, L., Baroni, G. S., Franchitto, A., Baiocchi, L., Glaser, S. S., Le Sage, G., Folli, F., et al. (2000) · Gastroenterology · doi:10.1053/gast.2000.20184 · Cited by 196
Analysis of risk factors for the development of liver disease associated with cystic fibrosis
Colombo, C., Apostolo, M. G., Ferrari, M., Seia, M., Genoni, S., Giunta, A., & Sereni, L. P. (1994) · The Journal of Pediatrics · doi:10.1016/s0022-3476(94)70361-2 · Cited by 189
Self-citationOutcome of cystic fibrosis-associated liver cirrhosis: management of portal hypertension
Debray, D., Lykavieris, P., Gauthier, F., Dousset, B. E., Sardet, A., Munck, À., Laselve, H., & Bernard, O. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80166-4 · Cited by 142
Diseases of the Liver and Biliary System
Beuers, U. H. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80343-1 · Cited by 130
The effect of estrogen and tamoxifen on hepatocyte proliferation in Vivo and in Vitro
Francavilla, A., Polimeno, L., Leo, A. D., Barone, M., Ove, P., Coetzee, M. L., Eagon, P. K., Makowka, L., Ambrosino, G., Mazzaferro, V., et al. (1989) · Hepatology · doi:10.1002/hep.1840090417 · Cited by 128
Ursodeoxycholic Acid Therapy in Cystic Fibrosis—Associated Liver Disease: A Dose–Response Study
Colombo, C., Crosignani, A., Assaisso, M., Battezzati, P. M., Podda, M., Giunta, A., Zimmer-Nechemias, L., & Setchell, K. D. R. (1992) · Hepatology · doi:10.1002/hep.1840160412 · Cited by 127
Self-citationCholangiocyte Biology and Cystic Fibrosis Liver Disease
Feranchak, A. P., & Sokol, R. J. (2001) · Seminars in Liver Disease · doi:10.1055/s-2001-19030 · Cited by 127
Clinical and Genetic Risk Factors for Cystic Fibrosis-related Liver Disease
Wilschanski, M. A., Rivlin, J., Cohen, S., Augarten, A., Blau, H., Aviram, M., Bentur, L., Springer, C., Vila, Y., Branski, D., et al. (1999) · PEDIATRICS · doi:10.1542/peds.103.1.52 · Cited by 124
An ultrasound scoring system for the diagnosis of liver disease in cystic fibrosis
Williams, S. G. J., Evanson, J. E., Barrett, N. K., Hodson, M. E., Boultbee, J. E., & Westaby, D. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80444-7 · Cited by 110
A prognostic model for the prediction of survival in cystic fibrosis
Hayllar, K. M., Williams, S. G., Wise, A. E., Pouria, S., Lombard, M., Hodson, M. E., & Westaby, D. (1997) · Thorax · doi:10.1136/thx.52.4.313 · Cited by 88
Recruiting collapsed lung through collateral channels with positive end-expiratory pressure.
Andersen, J. B., Qvist, J., & Kann, T. (1979) · PubMed · Cited by 85
Duthie, A., Doherty, D. G., Williams, C., Scott-Jupp, R. H., Warner, J. O., Tanner, S. M., Williamson, R., & Mowat, A. P. (1992) · Hepatology · doi:10.1002/hep.1840150418 · Cited by 83
Kinnman, N., Lindblad, A., Housset, C., Buentke, E., Scheynius, A., Strandvik, B., & Hultcrantz, R. W. (2000) · Hepatology · doi:10.1053/jhep.2000.9111 · Cited by 77
Feinstein, A. R., Pritchett, J. A., & Schimpff, C. R. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.123.3.323 · Cited by 70
Liver involvement in cystic fibrosis
Colombo, C., Crosignani, A. L., & Battezzati, P. M. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80299-2 · Cited by 53
Self-citation
Cited by
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Turck, D., Braegger, C. P., Colombo, C., Declercq, D., Morton, A., Pancheva, R., Robberecht, E., Stern, M., Strandvik, B., Wolfe, S., et al. (2016) · Clinical Nutrition · doi:10.1016/j.clnu.2016.03.004 · Cited by 526
Self-citationBest practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease
Debray, D., Kelly, D., Houwen, R., Strandvik, B., & Colombo, C. (2011) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(11)60006-4 · Cited by 432
Self-citationGenetic Modifiers of Liver Disease in Cystic Fibrosis
Bartlett, J. R. (2009) · JAMA · doi:10.1001/jama.2009.1295 · Cited by 308
Squires, R. H., Ng, V., Romero, R., Ekong, U., Hardikar, W., Emre, S., & Mazariegos, G. V. (2014) · Hepatology · doi:10.1002/hep.27191 · Cited by 254
Metadata
- Authors
- Colombo, C., Battezzati, P. M., Crosignani, A., Morabito, A., Costantini, D., Padoan, R., & Giunta, A.
- Venue
- Hepatology
- Published
- 2002-12
- Volume
- 36
- Issue
- 6
- Pages
- 1374-1382
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1993309320
- Cited by
- 377
- References
- 29
- FWCI
- 9.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.